Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Vanda Pharmaceuticals Inc. | w81923e10vk.htm |
| EX-32.2 - EXHIBIT 32.2 - Vanda Pharmaceuticals Inc. | w81923exv32w2.htm |
| EX-32.1 - EXHIBIT 32.1 - Vanda Pharmaceuticals Inc. | w81923exv32w1.htm |
| EX-31.1 - EXHIBIT 31.1 - Vanda Pharmaceuticals Inc. | w81923exv31w1.htm |
| EX-31.2 - EXHIBIT 31.2 - Vanda Pharmaceuticals Inc. | w81923exv31w2.htm |
| EX-10.41 - EXHIBIT 10.41 - Vanda Pharmaceuticals Inc. | w81923exv10w41.htm |
| EX-10.38 - EXHIBIT 10.38 - Vanda Pharmaceuticals Inc. | w81923exv10w38.htm |
| EX-10.40 - EXHIBIT 10.40 - Vanda Pharmaceuticals Inc. | w81923exv10w40.htm |
| EX-10.39 - EXHIBIT 10.39 - Vanda Pharmaceuticals Inc. | w81923exv10w39.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8
(No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567 and
No. 333-171962) and on Form S-3 (No. 333-171963) of Vanda Pharmaceuticals Inc. of our report dated
March 10, 2011 relating to the financial statements and the effectiveness of internal control over
financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
March 10, 2011
March 10, 2011